Adam G. Kreutzer

Adam G. Kreutzer

Auto-generated profile, based on publicly available information

Adam G. Kreutzer

Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SZSheng Zhang
Sheng Zhang
MKMaj Krumberger
Maj Krumberger
MMMichael A. Morris
Michael A. Morris
CPChelsea Marie T. Parrocha
Chelsea Marie T. Parrocha
AKAdam G. Kreutzer
Adam G. Kreutzer
JNJames S. Nowick
James S. Nowick

20 August 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
PSPatrick J. Salveson
Patrick J. Salveson
SHSepehr Haerianardakani
Sepehr Haerianardakani
ATAlexander Thuy-Boun
Alexander Thuy-Boun
SYStan Yoo
Stan Yoo
AKAdam G. Kreutzer
Adam G. Kreutzer
JNJames S. Nowick
James S. Nowick

1 October 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AKAdam G. Kreutzer
Adam G. Kreutzer
MKMaj Krumberger
Maj Krumberger
EDElizabeth Diessner
Elizabeth Diessner
CPChelsea Marie T. Parrocha
Chelsea Marie T. Parrocha
MMMichael A. Morris
Michael A. Morris
JNJames S. Nowick
James S. Nowick
This paper presents the design and study of a first-in-class cyclic peptide inhibitor against the SARS-CoV-2 main protease (Mpro). The cyclic peptide inhibitor is designed to mimic the conformation of a substrate at a C-terminal autolytic cleavage site of Mpro. The cyclic peptide contains a [4-(2-aminoethyl)phenyl]-acetic acid (AEPA) linker that is designed to enforce a conformation that mimics a peptide substrate of Mpro. In vitro evaluation of the cyclic peptide inhibitor reveals that the inhibitor exhibits modest activity against Mpro and does not appear to be cleaved by the enzyme. Conformational searching predicts that the cyclic peptide inhibitor is fairly rigid, adopting a favorable conformation for binding to the active site of Mpro. Computational docking to the SARS-CoV-2 Mpro suggests that the cyclic peptide inhibitor can bind the active site of Mpro in the predicted manner. Molecular dynamics simulations provide further insights into how the cyclic peptide inhibitor may bind the active site of Mpro. Although the activity of the cyclic peptide inhibitor is modest, its design and study lays the groundwork for the development of additional cyclic peptide inhibitors against Mpro with improved activities.

1 October 2021 in Current Opinion in Chemical Biology
Verified
Journal Article
Open access
TSTuan D. Samdin
Tuan D. Samdin
AKAdam G. Kreutzer
Adam G. Kreutzer
JNJames S. Nowick
James S. Nowick
The assembly of amyloidogenic peptides and proteins, such as the β-amyloid peptide, α-synuclein, huntingtin, tau, and islet amyloid polypeptide, into amyloid fibrils and oligomers is directly linked to amyloid diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases, frontotemporal dementias, and type II diabetes. Although amyloid oligomers have emerged as especially important in amyloid diseases, high-resolution structures of the oligomers formed by full-length amyloidogenic peptides and proteins have remained elusive. Investigations of oligomers assembled from fragments or stabilized β-hairpin segments of amyloidogenic peptides and proteins have allowed investigators to illuminate some of the structural, biophysical, and biological properties of amyloid oligomers. Here, we summarize recent advances in the application of these peptide model systems to investigate and understand the structures, biological properties, and biophysical properties of amyloid oligomers.